PhRMA Says Integrilin FCA Suit Stifles Free Speech Rights
By Daniel Wilson ( August 18, 2014, 3:24 PM EDT) -- The Pharmaceutical Research and Manufacturers of America on Friday urged a California federal court to dismiss a whistleblower's False Claims Act suit accusing two drugmakers of misbranding heart medication Integrilin and of paying kickbacks to doctors, saying the off-label claims in the case stepped on the companies' free speech rights....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.